Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

64.10USD
1:31am IST
Change (% chg)

$-0.06 (-0.09%)
Prev Close
$64.16
Open
$64.21
Day's High
$64.34
Day's Low
$63.50
Volume
2,498,778
Avg. Vol
2,531,982
52-wk High
$68.12
52-wk Low
$45.46

ABBV.N

Chart for ABBV.N

About

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and... (more)

Overall

Beta: 1.50
Market Cap(Mil.): $104,487.30
Shares Outstanding(Mil.): 1,628.54
Dividend: 0.57
Yield (%): 3.55

Financials

  ABBV.N Industry Sector
P/E (TTM): 18.40 36.88 36.64
EPS (TTM): 3.49 -- --
ROI: 11.38 14.53 14.01
ROE: 102.66 15.37 14.97

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc , beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. | Video

23 Aug 2016

Pfizer boosts cancer drug roster with $14 billion Medivation deal

Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.

23 Aug 2016

UPDATE 5-Pfizer boosts cancer drug roster with $14 bln Medivation deal

Aug 22 Pfizer Inc, beating out numerous other bidders, said it agreed to buy U.S. cancer drug company Medivation Inc for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster.

23 Aug 2016

Elliott Associates sues AbbVie over failed bid for Shire

Aug 5 AbbVie Inc said hedge fund Elliott Associates LP has sued the pharmaceuticals company alleging that it had made misrepresentations and omissions related to a failed attempt to buy Dublin-based Shire Plc .

06 Aug 2016

UPDATE 2-Drugmaker AbbVie bumps up profit forecast on strong Humira sales

July 29 AbbVie Inc posted higher-than-expected quarterly profit and revenue, driven by demand for its flagship drug Humira, and raised its earnings forecast for the year.

29 Jul 2016

AbbVie revenue jumps 17.8 pct on higher demand for drug Humira

July 29 AbbVie Inc's quarterly net revenue jumped 17.8 percent, driven by demand for its top-selling treatment, Humira.

29 Jul 2016

BRIEF-AbbVie initiates late stage study of venetoclax in patients with relapsed or refractory multiple myeloma

* Venetoclax is being developed by abbvie and genentech, a member of roche group

29 Jul 2016

BRIEF-Abbvie receives U.S. FDA approval of once-daily VIEKIRA XR

* Abbvie receives U.S. FDA approval of once-daily VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of genotype 1 chronic Hepatitis C

26 Jul 2016

Samsung Bioepis seeks Europe approval for its Humira copy

SEOUL Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.

18 Jul 2016

UPDATE 1-Samsung Bioepis seeks Europe approval for its Humira copy

* European Medicines Agency reviewing Samsung Bioepis' application

18 Jul 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $119.34 -0.13
Pfizer Inc. (PFE.N) $34.80 -0.08
Novartis AG (NOVN.S) CHF77.40 -0.70
Merck & Co., Inc. (MRK.N) $62.79 +0.08
Roche Holding Ltd. (ROG.S) CHF239.80 -3.10
Roche Holding Ltd. (RO.S) CHF240.30 -3.90
Abbott Laboratories (ABT.N) $42.02 -0.81
Eli Lilly and Co (LLY.N) $77.75 -0.02
Sanofi SA (SASY.PA) €69.07 -0.62

Earnings vs. Estimates